← SynDRA
CALCIPOTRIENE
SynDRA canonical compound SYN0023116 — structure-anchored drug synonym record
| Clinical phase | Launched |
| Approval status | Approved · Rx/OTC |
| Primary target(s) | VDR |
| Mechanism of action | vitamin D receptor agonist |
| Indication | psoriasis |
| Disease area | dermatology |
All known targets
Mechanisms of action (all sources)
- VDR AGONIST
- Vitamin D receptor agonist
- VDR ANTAGONIST
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- PTGS2
- NR1I2
- ADORA1
- OPRD1
- HTR1A
- HTR2A
- HTR2B
- HTR2C
- HTR3A
- KCNH2
- MAOA
- MC3R
- MLNR
- NPY1R
- NR3C1
- OPRK1
- ADORA2A
- OPRM1
- PDE3A
- PDE4D
- PGR
- SAMHD1
- SLC29A1
- SLC6A2
- SLC6A3
- SLC6A4
- TBXA2R
- TDP1
- HRH3
- HRH2
- HRH1
- HDAC6
- ADORA3
- ADRA1A
- ADRA2A
- ADRA2B
- ADRA2C
- ADRB1
- ADRB2
- AGTR1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Dermatologic Agents
- Vitamin D Analog
ATC classes
- D05A · ANTIPSORIATICS FOR TOPICAL USE
Cross-references
Synonyms
- CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE
- CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE
- Calcitrene
- DOVONEX
- Dovonex
- ENSTILAR
- SORILUX
- Sorilux
- TACLONEX
- WYNZORA
- calcipotriol
- calciptriol
- daivonex
- dovonex
- calcipotriene hydrate
- calcipotriol hydrate
- Calcipotriol
- Calcipotriene hydrate
- Calcipotriol hydrate
- Calcipotriene monohydrate
- Calcipotriol anhydrous
- Calcipotriol monohydrate
- Calciptriol
- MC-903
- PRI-2201
- Calcipotriene component of enstilar
- Calcipotriene component of taclonex
- Calcipotriene component of wynzora
- Calcipotriene hydrate component of taclonex
- Dovobet
- Enstilar
- Xamiol
- Divonex
- BMS-181161
- Daivonex (TN)
- Dovonex (TN)
- 1-ALPHA,24S-(OH)2-22-ENE-26,27-DEHYDROVITAMIN D3
Reported adverse events
- Rash
- Erythema
- Burning sensation
- Skin atrophy
- Skin irritation
- Psoriasis
- Dry skin
- Folliculitis
- Headache
- Pain
- Pruritus
- Application site pruritus
Look up CALCIPOTRIENE in the interactive SynDRA portal →